08:00 , Jan 7, 2016 |  BC Innovations  |  Distillery Therapeutics

Therapeutics: Leukotriene C4 (LTC4); cysteinyl leukotriene receptor 2 (CYSLTR2; CysLT2); CysLT1

Other INDICATION: Poisoning Cell culture and mouse studies suggest inhibiting LTC4 or its receptors, CysLT1 and CYSLTR2 , could help treat chemotherapy-related toxicity. In a HeLa-derived cell line, the generic chemotherapies doxorubicin and 5-fluorouracil (5-FU)...
07:00 , Mar 29, 2012 |  BC Innovations  |  Distillery Therapeutics

Indication: Dermatology

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Dermatology Dermatitis Cysteinyl leukotriene receptor 2 (CYSLTR2; CysLT2); leukotriene C4 synthase (LTC4S) Mouse studies suggest inhibiting leukotriene C4 signaling through LTC4S and...
08:00 , Feb 11, 2008 |  BC Week In Review  |  Company News

Amira, GlaxoSmithKline deal

Amira granted GlaxoSmithKline exclusive, worldwide rights to develop, manufacture and commercialize 5-Lipoxygenase Activating Protein ( FLAP ) inhibitors to treat respiratory and cardiovascular disease. Inhibiting FLAP in turn inhibits cysteinyl leukotriene receptor 1 (CysLT1) ,...
02:34 , Feb 5, 2008 |  BC Extra  |  Company News

GlaxoSmithKline in-licenses Amira's FLAP inhibitors

Amira (San Diego, Calif.) granted GlaxoSmithKline (LSE:GSK; NYSE:GSK) exclusive, worldwide rights to develop, manufacture and commercialize 5-lipoxygenase activating protein ( FLAP ) inhibitors to treat respiratory and cardiovascular diseases. Inhibiting FLAP in turn inhibits cysteinyl...
01:18 , Mar 24, 2007 |  BC Extra  |  Financial News

Amira raises $25 million

Amira (San Diego, Calif.) raised $25 million in a series B round led by Novo A/S. Existing investors Avalon ; Prospect Venture Partners; and Versant Ventures also participated. Amira expects its AM-103 to enter a...
08:00 , Nov 13, 2006 |  BioCentury  |  Emerging Company Profile

Amira: Beyond Singulair

Based on the work of CSO Peppi Prasit, Amira Pharmaceuticals Inc. is developing compounds to treat inflammation, including one that inhibits multiple targets in the leukotriene pathway to treat asthma. Prasit believes the compound, AM-103,...